A Phase 2 interventional study of Guselkumab Dose 1 and Guselkumab Dose 2 in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Completed at 82 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-12.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 14th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2018, is one of 5 in phase 2, and was the 21st registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Janssen-Cilag Pharma GmbH · Sites in Austria
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 30 more countries
Ages 18+
Janssen-Cilag A.G., Switzerland · Sites in Switzerland
Ages 18+
Xian-Janssen Pharmaceutical Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 18 · Phase 4 2
First in 2002; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 205 across the 28 interventional studies, 200 across the 15 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
4 of the studies in Colitis, Ulcerative by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT02808780Janssen Biotech, Inc.An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | 2026-12-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the clinical efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (UC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive guselkumab Dose 1 as intravenous (IV) infusion and Dose 2 as subcutaneous (SC) injection; and golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2 · Drug: Golimumab Dose 1 · Drug: Golimumab Dose 2 · Drug: Placebo
Participants will receive guselkumab Dose 1 as IV infusion, Dose 2 as SC injection and placebo to maintain the blind.
Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2 · Drug: Placebo
Participants will receive golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
Drug: Golimumab Dose 1 · Drug: Golimumab Dose 2 · Drug: Placebo
Guselkumab Dose 1 will be administered as IV infusion.
Guselkumab Dose 2 will be administered as SC injection.
Golimumab Dose 1 will be administered as SC injection.
Golimumab Dose 2 will be administered as SC injection.
Placebo will be administered.
Combination Phase: Percentage of Participants Who Achieved Clinical Response at Week 12
Clinical response was defined as a decrease from baseline in the Mayo score greater than or equal to (\>=) 30 percent (%) and \>=3 points with either a decrease from baseline in the rectal bleeding subscore (RBS) \>=1 or a RBS of 0 or 1. The Mayo score was calculated as the sum of 4 subscores (stool frequency, rectal bleeding, physician's global assessment, and endoscopy findings - each with score range of 0 (normal activity) to 3 (severe activity) and a total score range of 0 to 12 points. A score of 3 to 5 points indicates mildly active disease, a score of 6 to 10 points indicates moderately active disease, and a score of 11 to 12 points indicates severely active disease. Higher scores indicate more severity. This outcome measure was analyzed for combination phase only as preplanned in the protocol.
Time frame: Week 12
Combination Phase: Percentage of Participants Who Achieved Clinical Remission at Week 12
Clinical remission was defined as the Mayo score less than or equal to (\<=) 2 with no individual subscore greater than (\>) 1. The Mayo score was calculated as the sum of 4 subscores (stool frequency, rectal bleeding, physician's global assessment, and endoscopy findings) each with score range of 0 (normal activity) to 3 (severe activity) and a total score range of 0 to 12 points. A score of 3 to 5 points indicates mildly active disease, a score of 6 to 10 points indicates moderately active disease, and a score of 11 to 12 points indicates severely active disease. Higher scores indicate more severity. This outcome measure was analyzed for combination phase only as preplanned in the protocol.
Time frame: Week 12
| Milestone | Combination Phase: Golimumab Monotherapy | Combination Phase: Guselkumab Monotherapy | Combination Phase: Combination Therapy | Monotherapy Phase: Golimumab Monotherapy | Monotherapy Phase: Guselkumab Monotherapy | Monotherapy Phase: Combination Therapy | Safety Follow-up: Golimumab Monotherapy | Safety Follow-up: Guselkumab Monotherapy | Safety Follow-up: Combination Therapy |
|---|---|---|---|---|---|---|---|---|---|
| Started | 72 | 71 | 71 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 67 | 70 | 71 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Combination Phase: Golimumab Monotherapy | Combination Phase: Guselkumab Monotherapy | Combination Phase: Combination Therapy | Monotherapy Phase: Golimumab Monotherapy | Monotherapy Phase: Guselkumab Monotherapy | Monotherapy Phase: Combination Therapy | Safety Follow-up: Golimumab Monotherapy | Safety Follow-up: Guselkumab Monotherapy | Safety Follow-up: Combination Therapy |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 67 | 70 | 71 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 62 | 67 | 65 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 5 | 3 | 6 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 4 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Milestone | Combination Phase: Golimumab Monotherapy | Combination Phase: Guselkumab Monotherapy | Combination Phase: Combination Therapy | Monotherapy Phase: Golimumab Monotherapy | Monotherapy Phase: Guselkumab Monotherapy | Monotherapy Phase: Combination Therapy | Safety Follow-up: Golimumab Monotherapy | Safety Follow-up: Guselkumab Monotherapy | Safety Follow-up: Combination Therapy |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 65 | 60 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 55 | 58 | 55 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 7 | 5 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 2 |
Clinical response was defined as a decrease from baseline in the Mayo score greater than or equal to (\>=) 30 percent (%) and \>=3 points with either a decrease from baseline in the rectal bleeding subscore (RBS) \>=1 or a RBS of 0 or 1. The Mayo score was calculated as the sum of 4 subscores (stool frequency, rectal bleeding, physician's global assessment, and endoscopy findings - each with score range of 0 (normal activity) to 3 (severe activity) and a total score range of 0 to 12 points. A score of 3 to 5 points indicates mildly active disease, a score of 6 to 10 points indicates moderately active disease, and a score of 11 to 12 points indicates severely active disease. Higher scores indicate more severity. This outcome measure was analyzed for combination phase only as preplanned in the protocol.
| Percentage of participants | Combination Phase: Golimumab Monotherapy | Combination Phase: Guselkumab Monotherapy | Combination Phase: Combination Therapy |
|---|---|---|---|
| Combination Phase: Percentage of Participants Who Achieved Clinical Response at Week 12 | 61.1 | 74.6 | 83.1 |
Clinical remission was defined as the Mayo score less than or equal to (\<=) 2 with no individual subscore greater than (\>) 1. The Mayo score was calculated as the sum of 4 subscores (stool frequency, rectal bleeding, physician's global assessment, and endoscopy findings) each with score range of 0 (normal activity) to 3 (severe activity) and a total score range of 0 to 12 points. A score of 3 to 5 points indicates mildly active disease, a score of 6 to 10 points indicates moderately active disease, and a score of 11 to 12 points indicates severely active disease. Higher scores indicate more severity. This outcome measure was analyzed for combination phase only as preplanned in the protocol.
| Percentage of participants | Combination Phase: Golimumab Monotherapy | Combination Phase: Guselkumab Monotherapy | Combination Phase: Combination Therapy |
|---|---|---|---|
| Combination Phase: Percentage of Participants Who Achieved Clinical Remission at Week 12 | 22.2 | 21.1 | 36.6 |
Collected over Up to Week 50. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination Phase: Golimumab Monotherapy | 0/72 (0%) | 1/72 (1.4%) | 19/72 (26.4%) |
| Combination Phase: Guselkumab Monotherapy | 0/71 (0%) | 2/71 (2.8%) | 16/71 (22.5%) |
| Combination Phase: Combination Therapy | 0/71 (0%) | 1/71 (1.4%) | 14/71 (19.7%) |
| Monotherapy Phase: Golimumab Monotherapy | 0/67 (0%) | 3/67 (4.5%) | 12/67 (17.9%) |
| Monotherapy Phase: Guselkumab Monotherapy | 0/70 (0%) | 1/70 (1.4%) | 16/70 (22.9%) |
| Monotherapy Phase: Combination Therapy | 1/71 (1.4%) | 3/71 (4.2%) | 14/71 (19.7%) |
| Safety Follow-up: Golimumab Monotherapy | 0/58 (0%) | 0/58 (0%) | 3/58 (5.2%) |
| Safety Follow-up: Guselkumab Monotherapy | 1/65 (1.5%) | 2/65 (3.1%) | 2/65 (3.1%) |
| Safety Follow-up: Combination Therapy | 0/60 (0%) | 0/60 (0%) | 0/60 (0%) |
| Event | Combination Phase: Golimumab Monotherapy | Combination Phase: Guselkumab Monotherapy | Combination Phase: Combination Therapy | Monotherapy Phase: Golimumab Monotherapy | Monotherapy Phase: Guselkumab Monotherapy | Monotherapy Phase: Combination Therapy | Safety Follow-up: Golimumab Monotherapy | Safety Follow-up: Guselkumab Monotherapy | Safety Follow-up: Combination Therapy |
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/72 | 0/71 | 0/71 | 0/67 | 0/70 | 0/71 | 0/58 | 1/65 | 0/60 |
| Covid-19Infections and infestations | 0/72 | 0/71 | 0/71 | 0/67 | 0/70 | 0/71 | 0/58 | 1/65 | 0/60 |
| Adenocarcinoma of ColonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/72 | 0/71 | 0/71 | 0/67 | 0/70 | 0/71 | 0/58 | 1/65 | 0/60 |
| Chronic SinusitisInfections and infestations | 0/72 | 0/71 | 0/71 | 1/67 | 0/70 | 0/71 | 0/58 | 0/65 | 0/60 |
| Covid-19 PneumoniaInfections and infestations | 0/72 | 0/71 | 0/71 | 1/67 | 0/70 | 0/71 | 0/58 | 0/65 | 0/60 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/72 | 0/71 | 0/71 | 1/67 | 0/70 | 1/71 | 0/58 | 0/65 | 0/60 |
| BronchitisInfections and infestations | 0/72 | 0/71 | 0/71 | 0/67 | 1/70 | 0/71 | 0/58 | 0/65 | 0/60 |
| Atrial FibrillationCardiac disorders | 0/72 | 1/71 | 0/71 | 0/67 | 0/70 | 0/71 | 0/58 | 0/65 | 0/60 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/72 | 1/71 | 0/71 | 0/67 | 0/70 | 0/71 | 0/58 | 0/65 | 0/60 |
| InfluenzaInfections and infestations | 0/72 | 0/71 | 1/71 | 0/67 | 0/70 | 0/71 | 0/58 | 0/65 | 0/60 |
| Event | Combination Phase: Golimumab Monotherapy | Combination Phase: Guselkumab Monotherapy | Combination Phase: Combination Therapy | Monotherapy Phase: Golimumab Monotherapy | Monotherapy Phase: Guselkumab Monotherapy | Monotherapy Phase: Combination Therapy | Safety Follow-up: Golimumab Monotherapy | Safety Follow-up: Guselkumab Monotherapy | Safety Follow-up: Combination Therapy |
|---|---|---|---|---|---|---|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 8/72 | 1/71 | 4/71 | 5/67 | 4/70 | 6/71 | 3/58 | 1/65 | 0/60 |
| AnaemiaBlood and lymphatic system disorders | 5/72 | 6/71 | 4/71 | 2/67 | 6/70 | 0/71 | 0/58 | 1/65 | 0/60 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/72 | 5/71 | 1/71 | 2/67 | 2/70 | 6/71 | 0/58 | 0/65 | 0/60 |
| HeadacheNervous system disorders | 2/72 | 3/71 | 4/71 | 2/67 | 5/70 | 3/71 | 0/58 | 0/65 | 0/60 |
| NeutropeniaBlood and lymphatic system disorders | 2/72 | 4/71 | 2/71 | 1/67 | 2/70 | 2/71 | 0/58 | 0/65 | 0/60 |
| Age, Categorical(Participants) | Golimumab Monotherapy | Guselkumab Monotherapy | Combination Therapy | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 72 | 70 | 71 | 213 |
| >=65 years | 0 | 1 | 0 | 1 |
| Age, Continuous(years) | Golimumab Monotherapy | Guselkumab Monotherapy | Combination Therapy | Total |
|---|---|---|---|---|
| Mean | 38.1 ± 10.47 | 39.1 ± 13.67 | 37.8 ± 11.69 | 38.4 ± 11.96 |
| Sex: Female, Male(Participants) | Golimumab Monotherapy | Guselkumab Monotherapy | Combination Therapy | Total |
|---|---|---|---|---|
| Female | 30 | 31 | 37 | 98 |
| Male | 42 | 40 | 34 | 116 |
| Ethnicity (NIH/OMB)(Participants) | Golimumab Monotherapy | Guselkumab Monotherapy | Combination Therapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 6 | 5 | 15 |
| Not Hispanic or Latino | 68 | 65 | 66 | 199 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Golimumab Monotherapy | Guselkumab Monotherapy | Combination Therapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 1 | 4 |
| White | 67 | 71 | 70 | 208 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Golimumab Monotherapy | Guselkumab Monotherapy | Combination Therapy | Total |
|---|---|---|---|---|
| ARGENTINA | 0 | 1 | 3 | 4 |
| AUSTRALIA | 2 | 1 | 1 | 4 |
| BRAZIL | 2 | 3 | 4 | 9 |
| GERMANY | 0 | 1 | 1 | 2 |
| MEXICO | 2 | 2 | 0 | 4 |
| POLAND | 15 | 11 | 14 | 40 |
| RUSSIAN FEDERATION | 19 | 22 | 30 | 71 |
| UKRAINE | 27 | 25 | 16 | 68 |
| UNITED STATES | 5 | 5 | 2 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Dec 2020, 24 months.
Results were first posted in Dec 2023, 3 years after primary completion. A results delay was requested in Nov 2021.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 24 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →